卡培他滨二线治疗晚期胰腺癌54例临床疗效观察

目的观察卡培他滨二线治疗晚期胰腺癌的临床疗效。方法回顾性分析笔者所在医院54例晚期胰腺癌患者（均为一线化疗失败者），二线给予卡培他滨单药化疗。观察评价治疗效果。结果化疗2个疗程后，PR9例（16．67％），SD12例（22．22％），PD33例（61．11％）。患者客观有效率为16．67％，疾病控制率为38．89％。中位无进展生存时间为2．7个月，中位总生存时间9．8个月，3、4级主要毒副反应有中性粒细胞减少、手足综合征、腹泻、恶心、呕吐、口腔炎，不良反应可控。结论卡培他滨二线治疗胰腺癌能延长晚期胰腺癌患者无进展生存期和总生存期，且安全性好，不良反应可控制。

Clinical observation of capecitabine as second-line treatment for advanced pancreatic cancer on 54 cases

Objective To observe the clinical efficacy of capecitabine as second-line therapy in advanced pancreatic cancer. Methods Retrospective analysis of 54 patients in the author＇s hospital with advanced pancreatic cancer pa- tients, were first-line chemotherapy failure, second-line therapy was given capecitabine singJe-agent chemotherapy, to observe the evaluation of therapeutic effect. Results After 2 courses of chemotherapy, none of patients with CR, 9 cases （16.67%） with PR, 12 cases （22.22%） with SD, 33 cases （61.11%） with PD. The objective response was 16.67%, disease control rate was 38.89%, the median progression free survival time was 2.7 months, and median overall sur- vival time was 9.8 months. Class Ⅲ-Ⅳ major adverse reactions with neutropenia, hand-foot syndrome, diarrhea, nau- sea, vomiting, stomatitis, adverse reactions and controllable. Conclusion Capecitabine for second-line treatment of pancreatic cancer can prolong the patients with advanced pancreatic cancer progression free survival and overall sur- vival, with higher disease control rate, and good safety, adverse reactions can be controlled.